* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at ichk@ichk.org or (852) 2891 0581 for further details.

Liver cancer is the fifth most common cancer and the third leading cause of cancer deaths in Hong Kong according to the Centre for Health Protection. Patients with liver cancer may experience the following symptoms i.e. upper abdominal pain, easy satiety, palpable mass in the upper abdomen, hypoglycemia and weight loss.

Targeted therapy
Sorafenib is indicated for advanced renal cell carcinoma and unresectable hepatocellular carcinoma. It is a multikinase inhibitor that helps inhibit tumor growth and angiogenesis. Sorafenib has demonstrated efficacy and safety in treating HCC. In patients with advanced HCC, the median survival time is nearly 3 months longer for sorafenib than that for placebo. Adverse events profile of sorafenib is similar to that of placebo.